235 related articles for article (PubMed ID: 36125206)
1. Cholesterol not particle concentration mediates the atherogenic risk conferred by apolipoprotein B particles: a Mendelian randomization analysis.
Helgadottir A; Thorleifsson G; Snaebjarnarson A; Stefansdottir L; Sveinbjornsson G; Tragante V; Björnsson E; Steinthorsdottir V; Gretarsdottir S; Helgason H; Saemundsdottir J; Olafsson I; Thune JJ; Raja AA; Ghouse J; Olesen MS; Christensen A; Jacobsen RL; Dowsett J; Bruun MT; Nielsen K; Knowlton K; Nadauld L; Benediktsson R; Erikstrup C; Pedersen OB; Banasik K; Brunak S; ; Bundgaard H; Ostrowski SR; Sulem P; Arnar DO; Thorgeirsson G; Thorsteinsdottir U; Gudbjartsson DF; Stefansson K; Holm H
Eur J Prev Cardiol; 2022 Dec; 29(18):2374-2385. PubMed ID: 36125206
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: A multivariable Mendelian randomisation analysis.
Richardson TG; Sanderson E; Palmer TM; Ala-Korpela M; Ference BA; Davey Smith G; Holmes MV
PLoS Med; 2020 Mar; 17(3):e1003062. PubMed ID: 32203549
[TBL] [Abstract][Full Text] [Related]
3. Association of Genetically Predicted Lipid Levels With the Extent of Coronary Atherosclerosis in Icelandic Adults.
Björnsson E; Thorleifsson G; Helgadóttir A; Guðnason T; Guðbjartsson T; Andersen K; Grétarsdóttir S; Ólafsson Í; Tragante V; Ólafsson ÓH; Jónsdóttir B; Eyjólfsson GI; Sigurðardóttir Ó; Thorgeirsson G; Guðbjartsson DF; Thorsteinsdóttir U; Hólm H; Stefánsson K
JAMA Cardiol; 2020 Jan; 5(1):13-20. PubMed ID: 31746962
[TBL] [Abstract][Full Text] [Related]
4. High-throughput multivariable Mendelian randomization analysis prioritizes apolipoprotein B as key lipid risk factor for coronary artery disease.
Zuber V; Gill D; Ala-Korpela M; Langenberg C; Butterworth A; Bottolo L; Burgess S
Int J Epidemiol; 2021 Jul; 50(3):893-901. PubMed ID: 33130851
[TBL] [Abstract][Full Text] [Related]
5. Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content.
Marston NA; Giugliano RP; Melloni GEM; Park JG; Morrill V; Blazing MA; Ference B; Stein E; Stroes ES; Braunwald E; Ellinor PT; Lubitz SA; Ruff CT; Sabatine MS
JAMA Cardiol; 2022 Mar; 7(3):250-256. PubMed ID: 34773460
[TBL] [Abstract][Full Text] [Related]
6. Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk.
Ference BA; Kastelein JJP; Ginsberg HN; Chapman MJ; Nicholls SJ; Ray KK; Packard CJ; Laufs U; Brook RD; Oliver-Williams C; Butterworth AS; Danesh J; Smith GD; Catapano AL; Sabatine MS
JAMA; 2017 Sep; 318(10):947-956. PubMed ID: 28846118
[TBL] [Abstract][Full Text] [Related]
7. The Associations of Genetically Predicted Plasma Alanine with Coronary Artery Disease and its Risk Factors: A Mendelian Randomization Study.
Huang X; Zhao JV
Am J Clin Nutr; 2023 Nov; 118(5):1020-1028. PubMed ID: 37640107
[TBL] [Abstract][Full Text] [Related]
8. Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease.
Ference BA; Kastelein JJP; Ray KK; Ginsberg HN; Chapman MJ; Packard CJ; Laufs U; Oliver-Williams C; Wood AM; Butterworth AS; Di Angelantonio E; Danesh J; Nicholls SJ; Bhatt DL; Sabatine MS; Catapano AL
JAMA; 2019 Jan; 321(4):364-373. PubMed ID: 30694319
[TBL] [Abstract][Full Text] [Related]
9. Distinct metabolic features of genetic liability to type 2 diabetes and coronary artery disease: a reverse Mendelian randomization study.
Smith ML; Bull CJ; Holmes MV; Davey Smith G; Sanderson E; Anderson EL; Bell JA
EBioMedicine; 2023 Apr; 90():104503. PubMed ID: 36870196
[TBL] [Abstract][Full Text] [Related]
10. Age, Sex, and Cardiovascular Risk Attributable to Lipoprotein Cholesterol Among Chinese Individuals with Coronary Artery Disease: A Case-Control Study.
Wu TT; Zheng YY; Yang YN; Li XM; Ma YT; Xie X
Metab Syndr Relat Disord; 2019 May; 17(4):223-231. PubMed ID: 30720383
[No Abstract] [Full Text] [Related]
11. Pleiotropic Effects of
Jang SJ; Tuan WL; Hsu LA; Er LK; Teng MS; Wu S; Ko YL
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499290
[TBL] [Abstract][Full Text] [Related]
12. Circulating Lipoprotein Lipids, Apolipoproteins and Ischemic Stroke.
Yuan S; Tang B; Zheng J; Larsson SC
Ann Neurol; 2020 Dec; 88(6):1229-1236. PubMed ID: 32981134
[TBL] [Abstract][Full Text] [Related]
13. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men.
Pischon T; Girman CJ; Sacks FM; Rifai N; Stampfer MJ; Rimm EB
Circulation; 2005 Nov; 112(22):3375-83. PubMed ID: 16316964
[TBL] [Abstract][Full Text] [Related]
14. Associations of lipid measures with total occlusion in patients with established coronary artery disease: a cross-sectional study.
Li T; Yuan D; Wang P; Jia S; Zhang C; Zhu P; Song Y; Tang X; Zhao X; Gao Z; Yang Y; Gao R; Xu B; Yuan J
Lipids Health Dis; 2022 Nov; 21(1):118. PubMed ID: 36369093
[TBL] [Abstract][Full Text] [Related]
15. Associations of Lipids and Lipid-Lowering Drugs with Risk of Vascular Dementia: A Mendelian Randomization Study.
Zhang X; Geng T; Li N; Wu L; Wang Y; Zheng D; Guo B; Wang B
Nutrients; 2022 Dec; 15(1):. PubMed ID: 36615727
[TBL] [Abstract][Full Text] [Related]
16. Apolipoprotein B improves risk assessment of future coronary heart disease in the Framingham Heart Study beyond LDL-C and non-HDL-C.
Pencina MJ; D'Agostino RB; Zdrojewski T; Williams K; Thanassoulis G; Furberg CD; Peterson ED; Vasan RS; Sniderman AD
Eur J Prev Cardiol; 2015 Oct; 22(10):1321-7. PubMed ID: 25633587
[TBL] [Abstract][Full Text] [Related]
17. Dose-Response Associations of Lipid Traits With Coronary Artery Disease and Mortality.
Yang G; Mason AM; Wood AM; Schooling CM; Burgess S
JAMA Netw Open; 2024 Jan; 7(1):e2352572. PubMed ID: 38241044
[TBL] [Abstract][Full Text] [Related]
18. Beyond low-density lipoprotein cholesterol: defining the role of low-density lipoprotein heterogeneity in coronary artery disease.
Mudd JO; Borlaug BA; Johnston PV; Kral BG; Rouf R; Blumenthal RS; Kwiterovich PO
J Am Coll Cardiol; 2007 Oct; 50(18):1735-41. PubMed ID: 17964036
[TBL] [Abstract][Full Text] [Related]
19. Effects of apolipoprotein B on lifespan and risks of major diseases including type 2 diabetes: a mendelian randomisation analysis using outcomes in first-degree relatives.
Richardson TG; Wang Q; Sanderson E; Mahajan A; McCarthy MI; Frayling TM; Ala-Korpela M; Sniderman A; Smith GD; Holmes MV
Lancet Healthy Longev; 2021 Jun; 2(6):e317-e326. PubMed ID: 34729547
[TBL] [Abstract][Full Text] [Related]
20. Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review.
Sniderman AD; Thanassoulis G; Glavinovic T; Navar AM; Pencina M; Catapano A; Ference BA
JAMA Cardiol; 2019 Dec; 4(12):1287-1295. PubMed ID: 31642874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
